Osimertinib's OS Benefit in Resected NSCLC Persists 8 Years

Published Date: 17 Sep 2026

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A protein with new anticancer activity has been identified

2.

Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma

3.

Prostate cancer Q&A: Improving detection and reducing overtreatment

4.

AZD0486 Shows Good Efficacy in Relapsed/Refractory Follicular Lymphoma

5.

Use of marijuana and alcohol simultaneously is associated with worse outcomes.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot